Trial Profile
Open-label Study for an Exploration of Tumor Accumulation of the 18F Labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to '/= 0.1 mg Total Quantity) in Patients With Prostate Cancer or Other Malignant Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs BAY 949392 (Primary)
- Indications Cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Prostate cancer
- Focus Diagnostic use
- Sponsors Life Molecular Imaging
- 24 Apr 2014 New trial record